 Over 160 botanical extracts from our internal ingredient library were screened at a single concentration for inhibition of both DGAT-1 and GOAT. Botanicals that were identified as having at least 75 activity were then titrated to identify those with IC50 values 25 gml or less. We narrowed our list of viable ingredients by looking at those with activity in both the DGAT-1 and GOAT in vitro enzyme bioassay models. The top performing botanicals were then evaluated in a cellular model for DGAT-1 inhibition. Those with the highest inhibition activity in this model were considered lead candidates. A preliminary literature search was conducted and the final filter included factors such as cost and regulatory acceptability which results in the four ingredients being tested in the current clinical protocol.Our objective was to determine whether these four ingredients have similar mechanistic effects in the human body. 